Clinical outcomes of patients with mild COVID-19 following treatment with hydroxychloroquine in an outpatient setting
Mokhtari et al.
, Clinical outcomes of patients with mild COVID-19 following treatment with hydroxychloroquine in an outpatient..
, International Immunopharmacology, doi:10.1016/j.intimp.2021.107636
Retrospective 28,759 adult outpatients with mild COVID-19 in Iran, 7,295 treated with HCQ, showing significantly lower hospitalization and mortality with treatment.
risk of death, 69.7% lower, RR 0.30, p < 0.001, treatment 27 of 7,295 (0.4%), control 287 of 21,464 (1.3%), NNT 103, adjusted per study, odds ratio converted to relative risk.
risk of hospitalization, 35.3% lower, RR 0.65, p < 0.001, treatment 523 of 7,295 (7.2%), control 2,382 of 21,464 (11.1%), NNT 25, adjusted per study, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Mokhtari et al., 6 Apr 2021, retrospective, Iran, peer-reviewed, 11 authors, dosage 400mg bid day 1, 200mg bid days 2-5.
Abstract: Since January 2020 Elsevier has created a COVID-19 resource centre with
free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the
company's public news and information website.
Elsevier hereby grants permission to make all its COVID-19-related
research that is available on the COVID-19 resource centre - including this
research content - immediately available in PubMed Central and other
publicly funded repositories, such as the WHO COVID database with rights
for unrestricted research re-use and analyses in any form or by any means
with acknowledgement of the original source. These permissions are
granted for free by Elsevier for as long as the COVID-19 resource centre
International Immunopharmacology 96 (2021) 107636
Contents lists available at ScienceDirect
journal homepage: www.elsevier.com/locate/intimp
Clinical outcomes of patients with mild COVID-19 following treatment with
hydroxychloroquine in an outpatient setting
Majid Mokhtari a, Minoo Mohraz b, Mohammad Mehdi Gouya c, Hengameh Namdari Tabar d,
Jafar-Sadegh Tabrizi l, Katayoun Tayeri e, Saeide Aghamohamadi f, Zahra Rajabpoor g,
Manoochehr Karami h, Alireza Raeisi i, Hamid Rahmani j, Hossein Khalili k, *
Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran
Center for Communicable Disease Control (CDC), IHR National Focal Point, Ministry of Health & Medical Education, Tehran, Iran
Ministry of Health and Medical Education, AIDS/STI Control Dep. Ministry of Health and Medical Education, Eyvanak Street, Shahrak-e-Gharb, Tehran, Iran
Ministry of Health and Medical Education, Tehran Iran, Eyvanak Street, Shahrak-e-Gharb, Tehran, Iran
Health Service Management, Deputy of Health, Ministry of Health and Medical Education, Tehran, Iran
Ministry of Health and Medical Education, Eyvanak Street, Shahrak-e-Gharb, Tehran, Iran
Research Center for Health Sciences, Hamadan University of Medical Sciences, Hamadan, Iran
School of Medicine, Shiraz University of Medical Sciences, Shiraz Iran, Deputy of Health, Ministry of Health and Medical Education, Tehran, Iran
Department of Pharmacotherapy, Tehran University of Medical Sciences, Tehran, Iran
Department of Pharmacotherapy, Tehran University of Medical Sciences, Postal Code: 1417614411, P.O. Box: 14155/6451, Tehran, Iran
Tabriz Health Services Management Research Center, Tabriz, Iran
A R T I C L E I N F O
A B S T R A C T
The role of hydroxychloroquine (HCQ) in early outpatient management of mild coronavirus disease 2019
(COVID-19) needs further investigation.
This study was a multicenter, population-based national retrospective-cohort investigation of 28,759 adults
with mild COVID-19 seen at the network of Comprehensive Healthcare Centers (CHC) between March and
September 2020 throughout Iran. The baseline characteristics and outcome variables were extracted from the
national integrated health system database.
A total of 7295 (25.37%) patients who presented with mild COVID-19 within 3–7 days of symptoms onset
received HCQ (400 mg twice daily on day 1 followed by 200 mg twice daily for the next four days and were then
followed for 14 days).
The main outcome..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.